Clinical Trial Update: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of laquinimod (0.6 mg/day and 1.5 mg/day) versus placebo for primary progressive multiple sclerosis; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Primary Progressive Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2018-11-02